AIDS Therapy

Patient enrollment completed in phase I/II trial in AIDS

Published in Drug Week, September 10th, 2004

Advanced Viral Research Corp. (ADVR) announced that all 30 patients have been enrolled in its phase I/II clinical trial of AVR118 in patients with AIDS, thereby completing patient enrollment in this trial.

This phase I/II trial is being conducted at the Kaplan Medical Center in Israel in cachectic AIDS patients who may or may not be receiving anti-retroviral or highly active anti-retroviral therapy.

ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity.

This peptide-nucleic acid complex, which to date has demonstrated a very favorable safety profile, appears to stimulate the proinflammatory responses...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-09-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry